Abstract
There is a family of proteins - integrins, which are generally expressed at low levels on epithelial cells and mature endothelial cells, but they are highly expressed on the surface of both endothelial cells in tumor neovasculature and some tumor cells, including osteosarcomas, neuroblastomas, glioblastomas, melanomas, and carcinomas of the lung, the breast, the prostate, and the bladder. The alpha(v)beta(3) integrin plays a critical role in angiogenesis and tumor metastasis. Angiogenic blood vessels overexpress alpha(v)beta(3) integrin, as in tumor neovascularization, while alpha(v)beta(3) integrin expression in other microvascular beds and organs is limited. Therefore, alpha(v)beta(3) integrin is a suitable receptor for tumor-targeting therapy and imaging. The alpha(v)beta(3) integrin-targeting properties and the therapeutic potential of various radiolabeled RGD peptides are herein discussed.
Keywords: Integrin, alpha(v)beta(3), RGD peptide, therapy, imaging
Current Radiopharmaceuticals
Title: Advances in α(v)β(3) Integrin-Targeting Cancer Therapy and Imaging with Radiolabeled RGD Peptides
Volume: 2 Issue: 3
Author(s): Petar M. Mitrasinovic
Affiliation:
Keywords: Integrin, alpha(v)beta(3), RGD peptide, therapy, imaging
Abstract: There is a family of proteins - integrins, which are generally expressed at low levels on epithelial cells and mature endothelial cells, but they are highly expressed on the surface of both endothelial cells in tumor neovasculature and some tumor cells, including osteosarcomas, neuroblastomas, glioblastomas, melanomas, and carcinomas of the lung, the breast, the prostate, and the bladder. The alpha(v)beta(3) integrin plays a critical role in angiogenesis and tumor metastasis. Angiogenic blood vessels overexpress alpha(v)beta(3) integrin, as in tumor neovascularization, while alpha(v)beta(3) integrin expression in other microvascular beds and organs is limited. Therefore, alpha(v)beta(3) integrin is a suitable receptor for tumor-targeting therapy and imaging. The alpha(v)beta(3) integrin-targeting properties and the therapeutic potential of various radiolabeled RGD peptides are herein discussed.
Export Options
About this article
Cite this article as:
Mitrasinovic M. Petar, Advances in α(v)β(3) Integrin-Targeting Cancer Therapy and Imaging with Radiolabeled RGD Peptides, Current Radiopharmaceuticals 2009; 2 (3) . https://dx.doi.org/10.2174/1874471010902030214
DOI https://dx.doi.org/10.2174/1874471010902030214 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets Stem Cells and the Side Population Theory: A Critical Review
Current Tissue Engineering (Discontinued) The Universal Nature, Unequal Distribution and Antioxidant Functions of Melatonin and Its Derivatives
Mini-Reviews in Medicinal Chemistry Current Biological Therapies for Inflammatory Bowel Disease
Current Pharmaceutical Design Oxidative Stress Protection by Novel Telomerase Activators in Mesenchymal Stem Cells Derived from Healthy and Diseased Individuals
Current Molecular Medicine Novel Anti-Prostate Cancer Curcumin Analogues That Enhance Androgen Receptor Degradation Activity
Anti-Cancer Agents in Medicinal Chemistry To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Progress in Nanoparticulate Systems for Peptide, Proteins and Nucleic Acid Drug Delivery
Current Pharmaceutical Biotechnology The Clinical and Immunological Features of Patients with Primary Antibody Deficiencies
Endocrine, Metabolic & Immune Disorders - Drug Targets Antitumor Activity of Benzamide Riboside In Vitro and In Vivo
Current Medicinal Chemistry Follow the ATP: Tumor Energy Production: A Perspective
Anti-Cancer Agents in Medicinal Chemistry Insects Antiviral and Anticancer Peptides: New Leads for the Future?
Protein & Peptide Letters Assessment of Signal Peptides to Optimize Interleukin 2 (IL-2) Folding and Expression
Current Proteomics Identification of Inflammatory, Metabolic, and Cell Survival Pathways Contributing to Cerebral Small Vessel Disease by Postmortem Gene Expression Microarray
Current Neurovascular Research The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets Structural Features of the Interleukin-10 Family of Cytokines
Current Pharmaceutical Design Delivery of Nanoparticles for Treatment of Brain Tumor
Current Drug Metabolism Snake Venom Derived Molecules in Tumor Angiogenesis and its Application in Cancer Therapy; An Overview
Current Topics in Medicinal Chemistry A Novel Information Theoretic Approach to Gene Selection for Cancer Classification Using Microarray Data
Current Bioinformatics